"Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease".
Year: 2024
Type: review
Abstract: Acknowledgements: This publication is based upon work from COST Action CA21117, The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork [IMMUPARKNET], supported by COST (European Cooperation in Science and Technology) (www.cost.eu). Laura Muñoz-Delgado is financially supported by the “Juan Rodés” programme (JR23/00016) from the Instituto de Salud Carlos III and receives funding support from the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022). Caroline Williams-Grey receives financial support from the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the Cambridge Centre for Parkinson-Plus, and grant funding from the UKRI Medical Research Council (MR/W029235/1), Cure Parkinson’s, Parkinson’s UK, and the Rosetrees Trust. Gaetan Garraux is supported by ‘Fonds Rahier’, University of Liège and Fonds de la Recherche Scientifique (F.R.S.-FNRS) de Belgique. Gaëtan Garraux has also received support for travel or honorarium from AbbVie, Eurogenerics and Zambon. Diego Clemente has received funding support from Instituto de Salud Carlos III (PI18/00357, PI21/00302, PI24/00447, co-funded by the European Union, CIBERNED CB22/05/00016, “INVESTIGO” programme in the frame of the Plan para la Recuperación, Transformación y Resiliencia (European Union Next Generation funds), and EMD Serono R&D Agreement). Ines Figueira is supported by the the ERC—Grant No. 804229; through PeX—2022.02127.PTDC (PERCEPT) and through the R&D unit iNOVA4Health (LISBOA-01-0145-FEDER-007344; UIDB/04462/2020), and LS4FUTURE Associated Laboratory (LA/P/0087/2020).Pablo Mir has received financial support from the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704 and PI23/00512), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018 and PE-0186-2019), the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896). Pablo Mir has also received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Allergan, AbbVie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva and Zambon. Cristoforo Comi is supported by the AGING PROJECT—Department of Excellence—Università del Piemonte Orientale. Cristoforo Comi has received travel grants for meeting participation from Ecupharma, Bial and Novartis.
Authors: Muñoz-Delgado, Laura, Williams-Gray, Caroline H., Garraux, Gaetan, Clemente, Diego, Çakmak, Özgür Öztop, Greenland, Julia C., Figueira, Inês, Machín-Díaz, Isabel, Figueira, Inês, Pirovano, Elenamaria, di Flora, Alessia, Tournerie, Clotilde, Papoutsopoulou, Stamatia, Ertan, Sibel, Mir, Pablo, Comi, Cristoforo
Institutions: Consejo Superior de Investigaciones Científicas, Instituto de Salud Carlos III, Biomedical Research Networking Center on Neurodegenerative Diseases, Centro de Investigación Biomédica en Red, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, University of Cambridge, University of Liège, Koç University, NOVA Institute for Medical Systems Biology, Universidade Nova de Lisboa, University of Insubria, University of Thessaly, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: UK Research and Innovation, National Institute for Health and Care Research, Parkinson's UK, European Commission, Rosetrees Trust, Fonds De La Recherche Scientifique - FNRS, Université de Liège, Junta de Andalucía, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, EMD Serono, Medical Research Council, Instituto de Salud Carlos III, NIHR Cambridge Biomedical Research Centre
Awards: Las células mieloides supresoras como biomarcador de la capacidad endógena de remielinización en esclerosis múltiple, G2033069332, G2493601830, G2537968379, G4753630297, MRC Transition Support Award: The NET-PDD study - defining the roles of NEuroinflammation and Tau aggregation in Parkinson's Disease Dementia, G7106154494, Estudio del potencial de las células mieloides supresoras como bioindicadores de agresividad del curso clínico y de respuesta al tratamiento en esclerosis múltiple, La inmunorregulación en la agresividad de la esclerosis múltiple: valor predictivo y perspectivas terapéuticas
OpenAlex ID: W7120451998